ATE165973T1 - Sumatriptan enthaltende arzneimittel - Google Patents

Sumatriptan enthaltende arzneimittel

Info

Publication number
ATE165973T1
ATE165973T1 AT92103592T AT92103592T ATE165973T1 AT E165973 T1 ATE165973 T1 AT E165973T1 AT 92103592 T AT92103592 T AT 92103592T AT 92103592 T AT92103592 T AT 92103592T AT E165973 T1 ATE165973 T1 AT E165973T1
Authority
AT
Austria
Prior art keywords
film
drugs containing
solid dosage
coated solid
containing sumatriptan
Prior art date
Application number
AT92103592T
Other languages
English (en)
Inventor
John Malcolm Padfield
Ian Keith Winterborn
Anthony John Phillips
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE165973T1 publication Critical patent/ATE165973T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Waveguide Aerials (AREA)
  • Non-Reversible Transmitting Devices (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)
AT92103592T 1991-03-08 1992-03-02 Sumatriptan enthaltende arzneimittel ATE165973T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919104890A GB9104890D0 (en) 1991-03-08 1991-03-08 Compositions

Publications (1)

Publication Number Publication Date
ATE165973T1 true ATE165973T1 (de) 1998-05-15

Family

ID=42342461

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92103592T ATE165973T1 (de) 1991-03-08 1992-03-02 Sumatriptan enthaltende arzneimittel

Country Status (29)

Country Link
US (4) US5863559A (de)
EP (1) EP0503440B1 (de)
JP (1) JP2986546B2 (de)
KR (1) KR100202042B1 (de)
AT (1) ATE165973T1 (de)
AU (1) AU663303B2 (de)
BE (1) BE1005086A5 (de)
CA (1) CA2105180C (de)
CH (1) CH684242A5 (de)
CY (1) CY2011A (de)
CZ (1) CZ282352B6 (de)
DE (1) DE69225421T2 (de)
DK (1) DK0503440T3 (de)
ES (1) ES2117015T3 (de)
FR (1) FR2673538B1 (de)
GB (2) GB9104890D0 (de)
GE (1) GEP20012549B (de)
HK (1) HK19395A (de)
IE (1) IE920726A1 (de)
IL (1) IL101162A (de)
IT (1) IT1271495B (de)
MX (1) MX9200992A (de)
NL (1) NL9200423A (de)
NZ (1) NZ241873A (de)
OA (1) OA09812A (de)
RU (1) RU2098093C1 (de)
SG (1) SG169294G (de)
WO (1) WO1992015295A1 (de)
ZA (1) ZA921690B (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
ES2106818T3 (es) * 1991-10-30 1997-11-16 Glaxo Group Ltd Composicion multicapa que contiene antagonistas de histamina o secotina.
DE4314976C1 (de) * 1993-05-06 1994-10-06 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme zur Verabreichung von Wirkstoffen, Verfahren zu ihrer Herstellung und ihre Verwendung
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
GB9924717D0 (en) * 1999-10-19 1999-12-22 Glaxo Group Ltd Diagnostic
AT500063A1 (de) 1999-11-23 2005-10-15 Sandoz Ag Beschichtete tablettenkerne
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
US20030013753A1 (en) * 2001-06-05 2003-01-16 Ronald Aung-Din Transdermal migraine therapy
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
GB0129117D0 (en) * 2001-12-05 2002-01-23 Glaxo Group Ltd Pharmaceutical composition
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
WO2004009085A2 (en) * 2002-07-19 2004-01-29 Ranbaxy Laboratories Limited Taste masked sumatriptan tablets and processes for their preparation
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
WO2004060355A1 (en) * 2002-12-26 2004-07-22 Pozen Inc. Multilayer Dosage Forms Containing NSAIDs and Triptans
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2004076403A1 (en) * 2003-02-24 2004-09-10 Transform Pharmaceuticals, Inc. Sumatriptan crystalline forms, pharmaceutical compositions and methods
US20070184109A1 (en) * 2003-06-06 2007-08-09 Floyd Alison G Compositions comprising triptans and nsaids
EP1644004A4 (de) * 2003-06-20 2010-10-06 Ronald Aung-Din Topische therapie zur behandlung von migräne, muskelzerrungen, muskelspasmus, spastizität und verwandten zuständen
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
GB0400452D0 (en) * 2004-01-09 2004-02-11 Norton Healthcare Ltd A pharmaceutical composition
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
ES2624585T3 (es) * 2004-05-28 2017-07-17 Imaginot Pty Ltd. Sistema de suministro de compuesto terapéutico oral
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP1765300A2 (de) * 2004-06-10 2007-03-28 Duramed Pharmaceuticals, Inc. Formulierungen von sumatriptan zur absorption durch biologische membranen, und herstellungs- und anwendungsverfahren
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
KR20080012360A (ko) 2005-05-20 2008-02-11 얀센 파마슈티카 엔.브이. 설파미드 유도체의 제조 방법
AU2006317530B2 (en) * 2005-11-28 2011-09-01 Imaginot Pty Ltd Oral therapeutic compound delivery system
US20070166336A1 (en) * 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
TW200812573A (en) 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
JP2010522135A (ja) 2006-10-09 2010-07-01 チャールストン ラボラトリーズ,インコーポレイテッド 医薬組成物
CN101687788A (zh) * 2006-10-19 2010-03-31 奥斯拜客斯制药有限公司 取代的吲哚
EP2240022B1 (de) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Oxycodone und Promethazine enthaltende zweischichtige Tabletten
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
US8618157B2 (en) * 2008-06-20 2013-12-31 Alphapharm Pty. Ltd. Pharmaceutical formulation
US8809385B2 (en) 2008-06-23 2014-08-19 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8592424B2 (en) * 2008-06-30 2013-11-26 Afgin Pharma Llc Topical regional neuro-affective therapy
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
EP2480197B1 (de) 2009-09-25 2015-11-11 Dr. Reddy's Laboratories Ltd. Formulierungen mit triptanverbindungen
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
US10716766B2 (en) 2015-03-02 2020-07-21 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ,インコーポレイテッド 医薬組成物
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1170387B (it) * 1982-06-07 1987-06-03 Glaxo Group Ltd Composti eterociclici, procedimento per prepararli e composizioni farmaceutiche che li contengono
GB8332437D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB8419575D0 (en) * 1984-08-01 1984-09-05 Glaxo Group Ltd Chemical compounds
GB8928208D0 (en) * 1989-12-13 1990-02-14 Glaxo Group Ltd Medicaments
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions

Also Published As

Publication number Publication date
CZ184993A3 (en) 1994-06-15
JPH06505020A (ja) 1994-06-09
NL9200423A (nl) 1992-10-01
BE1005086A5 (fr) 1993-04-13
GB9104890D0 (en) 1991-04-24
DK0503440T3 (da) 1999-01-18
KR100202042B1 (ko) 1999-06-15
IT1271495B (it) 1997-05-30
JP2986546B2 (ja) 1999-12-06
NZ241873A (en) 1994-06-27
CA2105180C (en) 1999-08-17
CH684242A5 (fr) 1994-08-15
ITRM920155A1 (it) 1993-09-06
US6020001A (en) 2000-02-01
CZ282352B6 (cs) 1997-07-16
GB9204761D0 (en) 1992-04-15
RU2098093C1 (ru) 1997-12-10
AU663303B2 (en) 1995-10-05
DE69225421T2 (de) 1998-10-15
OA09812A (en) 1994-04-15
MX9200992A (es) 1992-09-01
AU1326492A (en) 1992-10-06
EP0503440A1 (de) 1992-09-16
EP0503440B1 (de) 1998-05-13
WO1992015295A1 (en) 1992-09-17
IE920726A1 (en) 1992-09-09
DE69225421D1 (de) 1998-06-18
IL101162A (en) 1997-11-20
ES2117015T3 (es) 1998-08-01
CY2011A (en) 1998-02-20
GB2254784B (en) 1994-11-16
IL101162A0 (en) 1992-11-15
SG169294G (en) 1995-04-28
US20020197318A1 (en) 2002-12-26
US5863559A (en) 1999-01-26
CA2105180A1 (en) 1992-09-09
US6368627B1 (en) 2002-04-09
FR2673538B1 (fr) 1995-05-12
HK19395A (en) 1995-02-17
ITRM920155A0 (it) 1992-03-06
ZA921690B (en) 1993-08-02
GB2254784A (en) 1992-10-21
GEP20012549B (en) 2001-10-25
FR2673538A1 (fr) 1992-09-11

Similar Documents

Publication Publication Date Title
ATE165973T1 (de) Sumatriptan enthaltende arzneimittel
RU93057724A (ru) Фармацевтическая композиция, способ ее получения и способ лечения
NO20022014L (no) En fast oral kontrollert frigjorende doseringsform inneholdende hydrokodon
ATE130758T1 (de) Arzneimittel zur intranasalen verabreichung, die ketorolac r enthalten.
AP1818A (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
MX9706449A (es) Composicion farmaceutica para compuestos de piperidinalcanol.
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
GR3015014T3 (en) Compositions for topical administration containing fluticasone propionate and oxiconazole or its salts.
SE9901572D0 (sv) New compounds
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
MY133438A (en) Morpholinobenzamide salts
RU96121556A (ru) Фармацевтические составы, содержащие ранитидин в низких дозах
IT1271354B (it) Preparazione di una forma farmaceutica atta a combattere l'iperinsulinismo contenente n-acetil cisteine e loro analoghi

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee